Shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) saw strong trading volume on Friday . 607,787 shares traded hands during trading, an increase of 2% from the previous session’s volume of 595,285 shares.The stock last traded at $3.59 and had previously closed at $3.38.

A number of equities analysts have commented on the company. HC Wainwright started coverage on Anthera Pharmaceuticals in a research note on Friday. They set a “buy” rating and a $10.00 price objective on the stock. Zacks Investment Research lowered Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 4th. Jefferies Group reiterated a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 30th. Finally, FBR & Co reiterated a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Anthera Pharmaceuticals has an average rating of “Buy” and an average price target of $9.58.

The firm has a 50 day moving average price of $3.38 and a 200 day moving average price of $3.52. The stock’s market cap is $156.16 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01. Equities research analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.25) earnings per share for the current fiscal year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.